NOT-AI-21-033: Notice of Early Expiration of PAR-19-346 "Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)"

Notice of Early Expiration of PAR-19-346 "Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)"

Notice Number:

NOT-AI-21-033

Key Dates

Release Date:

March 23, 2021

Related Announcements

PAR-19-346 - Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)
NOT-AI-21-032 - Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is to inform the extramural community of the early expiration of PAR-19-346 "Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)", effective immediately. The June 16, 2021 application due date is no longer available. The Key Dates section of the FOA has been modified to change the Expiration Date from September 8, 2022 to March 23, 2021.

Applicants are encouraged to consider applying to NOT-AI-21-032"Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies".

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Frosso Voulgaropoulou, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3205
Email: [email protected]